Treatment, Maternal outcomes and Effect on the fetus in early and middle pregnancy
In the 11 patients that were in early and middle pregnancy at COVID-19 diagnosis, gestational age ranged from 4 weeks to 26 weeks. Two (18.2%) presented with severe disease, 6 (54.5%) had moderate disease, and 3 (27.3%) were clinically mild. All 11 received antiviral treatment (Arbidol/Ribavirin/Lianhua Qingwen/Oseltamivir), 7 (63.6%) received antibiotic therapy, and 3 (27.3%) were treated with systemic glucocorticoids. None required mechanical ventilation, and all were cured.
One patient developed depression, and one (patient 11) experienced spontaneous abortion 16 days after she was diagnosed with COVID 19. Notably, 3 patients (6, 7 and 10) requested termination of their pregnancies owing to concerns about COVID-19, after they had recovered. Fetal growth was assessed by serial ultrasound scans every 2 weeks among the 7 women with ongoing pregnancies. No intrauterine growth retardation (IUGR) was observed during the study period (Table 3). Fetal surveillance with antenatal cardiotocography and umbilical arterial Doppler velocimetry was satisfactory.